First City Capital Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-672
Closed -$299K 165
2023
Q2
$299K Hold
672
0.18% 134
2023
Q1
$315K Hold
672
0.18% 131
2022
Q4
$345K Hold
672
0.21% 123
2022
Q3
$305K Hold
672
0.2% 125
2022
Q2
$324K Hold
672
0.2% 124
2022
Q1
$330K Hold
672
0.18% 129
2021
Q4
$300K Hold
672
0.17% 134
2021
Q3
$251K Hold
672
0.14% 146
2021
Q2
$247K Sell
672
-1
-0.1% -$382 0.14% 146
2021
Q1
$263K Buy
+673
New +$216K 0.15% 136
2020
Q4
Sell
-1,344
Closed -$393K 170
2020
Q3
$393K Buy
+1,344
New +$362K 0.15% 134
2016
Q2
Sell
-600
Closed -$83.4K 244
2016
Q1
$83.4K Hold
600
0.06% 214
2015
Q4
$83.7K Hold
600
0.06% 216
2015
Q3
$84K Hold
600
0.06% 220
2015
Q2
$98.5K Hold
600
0.07% 202
2015
Q1
$92.6K Hold
600
0.06% 208
2014
Q4
$75.4K Hold
600
0.05% 240
2014
Q3
$71.8K Hold
600
0.05% 247
2014
Q2
$64.6K Hold
600
0.05% 258
2014
Q1
$59.7K Buy
+600
New +$54.3K 0.04% 260

Other funds holding ELV

First City Capital Management's ELV Position: Q3 2023 in Review

First City Capital Management sold out of Elevance Health (ELV) in Q3 2023, closing a stake of 672 shares — an estimated $299K sold.

First City Capital Management first reported a position in ELV in Q1 2014 and held it in 20 quarters. The position peaked at $393K in Q3 2020. 1,523 funds tracked by Wall St. Rank hold ELV as of Q3 2023.

  • First City Capital Management reported no remaining Elevance Health position as of Q3 2023 after selling out during the quarter.
  • First City Capital Management sold 672 Elevance Health shares in Q3 2023, an estimated $299K.
  • First City Capital Management first reported a position in Elevance Health in Q1 2014 and held it in 20 quarters.
  • First City Capital Management's Elevance Health position peaked at $393K in Q3 2020.
  • 1,523 funds tracked by Wall St. Rank held Elevance Health as of Q3 2023.

Based on First City Capital Management's 13F filing for Q3 2023, filed 26 Oct 2023.